New study to test THC and CBD benefits for dementia-related agitation and anxiety
What this study can and cannot answer matters as much as the headline result. A placebo-controlled, double-blinded design is stronger than anecdote or uncontrolled reports, but it will still test a very specific group: people with late-stage dementia who are agitated and eligible for hospice care. That means any signal of benefit may not translate to earlier-stage dementia, community settings, or other forms of anxiety and distress.
For families and clinicians, the key question is not only whether symptoms ease, but whether the trade-offs are acceptable. THC-containing products can raise concerns about sedation, confusion, falls, appetite change, or interaction with other medicines, while CBD products are often discussed as gentler but are not automatically risk-free. In frail patients, even modest changes in alertness or balance may affect comfort, communication, and caregiving needs.
The study also sits in a broader evidence gap. Research on cannabis-derived compounds often shows mixed results because products, doses, and outcome measures vary widely. That makes it hard to generalize from one trial to another. If this research helps define who benefits, at what dose, and with what monitoring, it could be more useful than simply asking whether cannabis โworksโ in a broad sense.
For readers, the most practical takeaway is measured optimism. This is a step toward understanding whether cannabinoid-based options may help a difficult end-of-life symptom that currently has limited treatment choices. But until results are published, the most responsible interpretation is that promise remains plausible, not proven.
Research design
The placebo-controlled, double-blinded study is designed for dementia patients experiencing agitation at the end-of-life stage who are either receiving hospice care or who are eligible for hospice. At present, there are no FDA-approved medications to treat this aspect of dementia. As part of the study, participants will complete a baseline visit and will be randomly assigned to either a group receiving the active study drug or to one receiving a placebo. The active study will take place over 12 weeks and will include one screening visit, six in-person visits and five evaluations by phone. THC and CBD may provide relief for dementia-related anxiety.Before the end of the study, the participants will be able to request to continue their participation in the โOpen Label Extensionโ portion of the study. At this stage, all participants will receive the active drug and not the placebo. Pennington Biomedical facilitates the LiBBY study alongside 11 more research institutions. The research center is currently recruiting eligible participants alongside Georgetown University Medical Center, the University of Kentucky and the Ralph H. Johnson VA Medical Center. The facility works with hospice care providers in the US Capital Region and beyond. The large hospice group Carpenter Health Network is one of the providers helping to identify patients and caretakers who may be eligible. Raoul Manalac, medical director at St. Joseph Hospice โ Baton Rouge, states: โThe Carpenter Health Network is proud to join with other late-stage care facilities and networks to share this study with the families we work with daily.โSignificance and implications
Manalac highlights that dementia is accompanied by many challenges, with agitation and anxiety in particular being among the most frightening and frustrating for patients and families. He says that there are few options available to provide relief. โThis innovative study is driven by both the quest for new knowledge, as well as compassion for families dealing with dementia.โ Dr. John Kirwan, executive director of Pennington Biomedical, adds: โDementia, especially when coupled with agitation, can be frightening for patients and heartbreaking for caregivers, who frequently face burnout. As other studies have shown THC can help in treating post-chemotherapy nausea, the LiBBY study is a practical next step in exploring the benefits of these compounds and offering hope to those facing this difficult challenge.โ โDr. Keller and his colleagues have worked incredibly diligently to bring this study to Pennington Biomedical. We are proud to have this study here and to have it position the Center for similar studies in the future.โ At the same time, a recent randomizedย trialย of commercially sold cannabis products has found that CBD may be more effective in addressing anxiety than THC. Another study revealed that CBG (cannabigerol) canย reduceย anxiety and stress without intoxication. Meanwhile, in an interview withย Nutrition Insight, the Consumer Healthcare Products Association called on the US FDA to improve its current regulation and guidelines for CBD products.Enjoyed this article? Sign up for our newsletter to receive regular insights and stay connected.